- 1
- 2 <u>Title page</u>
- 3

Title: Changing species dynamics and species-specific associations observed between
 Anopheles and *Plasmodium* genera in Diebougou health district, southwest Burkina Faso

- 6
- 7 Authors: Lado P^{1^}, Gray LI^{1^}, Sougué E^{4^}, Knight AL¹, Sorensen M¹, Leon AS¹, Ring ME¹, Pugh
- 8 G¹, Randall JC¹, Coffin KL¹, Hemming-Schroeder E¹, Goodwin J², Wade M², Sproch H²,
- 9 Ouédraogo COW⁴, Dah SR⁴, Somé AF⁴, Dabiré RK⁴, Parikh S², Foy BD^{1*}
- 10

¹Center for Vector-borne Infectious Diseases, Department of Microbiology, Immunology and

- 12 Pathology, Colorado State University, Fort Collins, CO, USA; ²Department of Epidemiology of
- 13 Microbial Diseases, Yale School of Public Health, New Haven, CT, USA; ³Center for Innovative
- 14 Design and Analysis, University of Colorado Anschutz Medical Campus, Aurora, CO, USA;
- ⁴Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-
- 16 Dioulasso, Burkina Faso; ^These authors contributed equally; *Corresponding Author
- 17

18 <u>Abstract</u>

- 19 The prevalence of malaria parasite species in parts of Africa is rapidly changing and influenced
- 20 by detection methods. The natural vector competence and vectorial capacity of African
- 21 anophelines for human *Plasmodium* species has only been well described for *P. falciparum* and
- is unclear in the context of mixed and non-falciparum infections. Over the course of two clinical
- trials (2015 and 2019-2020) testing ivermectin for malaria control in the same region of Burkina
- Faso, we sampled participants' blood and their households for *Anopheles* spp. mosquitoes and
- 25 tested these samples for *Plasmodium* species. *Plasmodium* prevalence in participants and their
- blood samples was high in both trials. While *P. falciparum* mono-infections comprised most
 infections in the 1st trial, mixed and non-falciparum infections comprised 27% of infections in the
- infections in the 1st trial, mixed and non-falciparum infections comprised 27% of infections in the 2nd trial, with notable changes in species present within participants over time. Furthermore, *An.*
- 29 *gambiae* s.l. was the main vector captured, but *An. funestus* mosquitoes were unexpectedly
- 30 prevalent in the 2nd trial, and we found that parasite species prevalence differed in abdominal
- 31 and head+thorax tissues of these two vector species. Most notably, *P. falciparum* sporozoites
- 32 were significantly more prevalent than other parasite species in *An. gambiae* s.l. while *P. ovale*
- 33 sporozoites were significantly more prevalent than other parasite species in *An. funestus*. Our
- 34 data suggest differential vector competence for *Plasmodium* species at the study site, which
- 35 may significantly impact malaria epidemiology, disease prevalence and control efforts.
- 36
- 37
- 38 39
- 40
- 41
- 42
- 42 43
- 43 44

45 Introduction

46

47 Malaria, caused by *Plasmodium* parasites transmitted by *Anopheles* mosquitoes, is one of the 48 most prevalent infectious diseases in Africa and other parts of the tropics. Of the estimated 249 49 million cases worldwide, 48.5% occur in West Africa, Burkina Faso is among the most affected 50 countries, ranking 6th in malaria cases and 9th deaths globally (1). Efforts to control the disease 51 burden in the country, similar to other high transmission countries in West Africa, includes using 52 point-of-care (POC) rapid diagnostic tests (RDT) and treatment with artemisinin-based 53 combined therapies (ACT), intermittent preventative treatment in pregnancy (IPTp), and use of 54 seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus 55 amodiaquine (AQ). To control transmission, health authorities perform community distributions 56 of insecticide-treated bed nets (ITN) approximately every 2-4 years, which more recently includes distribution of nets containing more than one chemical (dual-chemistry nets), and less 57 58 often conduct indoor residual spraying (IRS) of insecticides in specific regions (2, 3). Despite 59 these efforts, the malaria burden in Burkina Faso has remained high with increasing incidence 60 for nearly a decade (4, 5).

61

62 Potential causes for the intransigence of malaria in Burkina Faso despite these intensive control

63 efforts are many. Socioeconomic factors such as high rates of poverty, limited community

64 uptake and/or compliance with parasite and vector control tools, political upheaval with high

65 migrant flows, and extensive artisanal gold mining across the country all likely contribute to the

66 current situation (6-11). Within- and between-species parasite diversity is also underappreciated

and represents an additional challenge of malaria control in high burden countries. Infections

68 with a diversity of genotypic clones of *Plasmodium falciparum (Pf)* are common in such settings

and correlated to higher malaria incidence among young children in many settings (12-14). In

center-west Burkina Faso, higher diversity (multiplicity of infection; MOI) of *Pf* genotypes among
 those presenting with malaria correlated with periods of higher malaria incidence, and overall

those presenting with malaria correlated with periods of higher malaria incidence, and overall
 MOI decreased with advancing age (15). In southwestern Burkina Faso, using amplicon deep

73 sequencing, we recently demonstrated that asymptomatic individuals harbored a mean of 3.1

74 distinct *Pf* clones per sampling timepoint spanning across wet and dry seasons, each of which

75 could theoretically have different genetics relating to antimalarial drug resistance,

76 immunogenicity, or other factors relating to disease processes (16).

77

78 Parasite species diversity also complicates malaria control, but a recognition of the scope of

such diversity within different African regions is only recently emerging. Reports over the past

80 several years have demonstrated unexpected or increasing prevalence of *Plasmodium malariae*

81 (*Pm*), with its unique 72-hour life cycle, and *P. ovale* (*Po*) species and *P. vivax* (*Pv*) with their

dormant hypnozoite stages in certain regions (17-19). More limited data from West Africa

83 suggest unexpected prevalence or increases in non-falciparum species in parts of Burkina Faso

and other countries (20-22). The lack of detection of non-falciparum species is not surprising

85 because these species tend to maintain lower peripheral parasite densities and therefore are

86 less likely to be detected by microscopy and RDTs (23-25). In addition, African countries nearly

87 universally lack treatment policies which support anti-relapse treatment of dormant hypnozoites

of *Po* species and *Pv*, leaving a persistent and unaddressed reservoir within the continent (26).

89

90 On the vector side, there is similarly high diversity both within and between mosquito species 91 across Burkina Faso which varies from the dry Sahel ecozone in the north with a short but 92 intense rainy season to the Sudanian ecozone in the south with a longer rainy season (27-37). 93 Anopheles gambiae s.s. and An. coluzzi typically have the highest human biting rates in rural 94 and semi-rural areas during the rainy seasons (38, 39), while An. arabiensis drives malaria 95 transmission in urban centers especially during the dry seasons (32). In other landscapes, 96 different species can be the primary vectors, including An. funestus group species around areas 97 with more permanent water sources such as dams, swamps and ponds (39-42), and An, nili 98 which breeds along the edges of rivers and streams in the south (43). Highly zoophagic and 99 exophagic vectors such as An. squamosis, An. rulipes, An. coustani, and An. pharoensis can 100 also be prevalent across landscapes in the south (43). These diverse vector species and their 101 varied bionomics can hamper vector control efficacy. For example, exophilic and exophagic 102 behaviors that limit exposure to ITN and IRS insecticides, plus increasing insecticide resistance 103 among these vectors due to exposure from both agriculture and malaria vector control efforts, 104 may be hampering the success of the limited vector control tools available (44).. The complexity 105 of parasite transmission from these diverse vectors also likely fosters malaria risk. For example, 106 malaria risk increases with vector density and blood feeding rates among persons with low ITN 107 use (45), and infection intensity and high MOI in different vector species can also drive 108 differential malaria risks or infections with unique genotypes (16, 46-49) 109 110 To develop new malaria control tools that might better control malaria in Burkina Faso, we have 111 conducted cluster-randomized control trials in the southwestern Diebougou district to test if

112 ivermectin mass drug administrations (MDA) can reduce malaria incidence. Ivermectin is a 113 widely used endectocide that exhibits mosquitocidal activity (50). The drug's strong safety 114 profile in humans and broad-spectrum anti-parasitic effects has allowed for its use in MDA to 115 control neglected filarial diseases (51), and ongoing efforts to test its ability to reduce the 116 survival of malaria vectors and limit malaria transmission (52-57). The first trial in Burkina Faso, 117 termed Repeat Ivermectin Mass Drug Administrations for control of Malaria (RIMDAMAL), was 118 conducted from July to November in 2015 and evaluated repeated low dose ivermectin MDA 119 given at 3-week intervals in treatment clusters compared to a single MDA in control clusters 120 (58), while the second trial, termed RIMDAMAL II, occurred in the same region over two 121 consecutive rainy seasons (from July to November in both 2019 and 2020) and evaluated high 122 dose ivermectin or placebo MDA given monthly (59). Additionally, in RIMDAMAL II, MDAs were 123 operationally paired with SMC distribution to children 3-59 months old in all clusters, which was 124 first implemented in the study area in 2018, in between the time of the two RIMDAMAL trials. 125 The RIMDAMAL trials are among several other cluster-randomized control trials that have 126 tested or are in the process of testing if ivermectin MDA can reduce malaria incidence or 127 parasite prevalence among participants in treated communities (60-62).

128

129 The outcomes of the RIMDAMAL trial have been published, and the primary and secondary

- 130 outcomes of the RIMDAMAL II trial will be presented elsewhere. In the process of analyzing the
- parasite and vector samples collected from these trials, we observed noticeable differences in
- the prevalence of different parasite species' infecting participants between the first and second

133 trial, some of whom participated in both trials. Most notably, in RIMDAMAL II, we observed

134 significant associations of specific vector species with different Plasmodium species that are

135 suggestive of differences in vector competence and/or vectorial capacity for certain parasite

136 species. In sub-Saharan Africa (SSA), despite Pf being the species most frequently detected

- 137 and responsible for the majority of clinical cases (63), Po and Pm can significantly contribute to
- 138 malaria epidemiology and have been observed to occur at high prevalence in parts of several 139 countries (18, 19, 21, 64-73) or increasing in prevalence over longitudinal studies within a
- 140 country (20). The data presented here shed light on vector-parasite interactions that may
- 141 influence malaria epidemiology observations in these and other studies.
- 142

143

144 Results

145 Organization and timelines surrounding the RIMDAMAL trials

146 The health district of Diebougou is in the southwest region of Burkina Faso in Bougouriba 147 province. The district has been conducting yearly MDA with single dose ivermectin (150 μ g/kg) 148 and albendazole (400 mg/kg) in all its communities for more than a decade to control 149 onchocerciasis and lymphatic filariasis. The RIMDAMAL trial was conducted during the 2015 150 rainy season in 8 clusters (villages) in the health district, while the RIMDAMAL II trial was

151 conducted during the 2019 and 2020 rainy seasons in 14 clusters of the district. Trial designs,

152 cluster selection and allocation in both trials are described elsewhere (58, 59). Briefly, in both

153 trials, clusters were randomized 1:1 between the treatment and control arms, and the trial 154 organizations and treatments and controls were different, however four clusters were common

155 among the two trials (Table 1). In RIMDAMAL, repeated low dose ivermectin MDA (single oral

156 dose, 150 µg/kg) was given at 3-week intervals in treatment clusters and compared to a single

157 MDA at the start of the trial in control clusters, while the RIMDAMAL II trial occurred over two

158 consecutive rainy seasons and repeated high dose ivermectin MDA (1 oral dose daily for 3 159 days; 300 µg/kg) was given at 1-month intervals in treatment clusters compared to placebo

160 MDA on the same schedule in control clusters. Furthermore, in RIMDAMAL II, MDA was

161 operationally paired with SMC distribution to children between 3-59 months old in all clusters.

162 which was instituted as national policy starting in 2017. A third, unrelated, cluster randomized

163 trial called the REACT trial was conducted from 2016-18 by a few of the authors, which had one

164 trial arm including ivermectin treatment of cattle, goats and sheep in the 2017 rainy season and 165

occurred in villages of the Diebougou health district that were not part of the RIMDAMAL II trial 166 (74, 75). District ITN distributions occurred in 2016 with standard pyrethroid-based nets, and at

167 the end of 2019 (between October 29-November 2) with new dual-chemistry (alpha-

168 cypermethrin and chlorfenapyr) Interceptor[®] G2 nets to better control insecticide-resistant

169 malaria vectors. An analysis of Normalized Difference Moisture Index (NDMI), a measure of

170 vegetation moisture content and indicator of land surface wetness, across the study areas from

171 2015-2020 revealed marked interannual variation as well as variation between clusters (Figure

172 1). Overall, the 2015 RIMDAMAL trial was conducted during a drier rainy season of those

173 analyzed for the study area, while both rainy seasons of RIMDAMAL II (2019 and 2020) were

174 relatively wet (Figure 1). NDMI was selected for analysis because it provides information on

175 both temporal precipitation and landscape heterogeneity which may correspond to differences in

176 larval habitat abundance (76).



Table 1 Timeline and organizational features of the RIMDAMAL trials and other malaria control trial									
and efforts in th	e Diebouaou h	ealth district.							
Event	Year								
	2015	2016	2017	2018	2019	2020			
RIMDAMAL trial	July 17 – November 22 <u>Treatment</u> DG, KK, KP, TJ <u>Control</u> DK , LM, ML, TG								
RIMDAMAL II trial					July 26 – November 13 Treatment BG, DK, DT, GB, KP, KS, SG Control (Placebo) DB, DL, MT, NB, NV, TG, TJ	July 20 – November 9 Treatment BG, DK , DT, GB, <u>KP</u> , <u>KS</u> , <u>SG</u> <u>Control (Placebo)</u> <u>DB, DL</u> , MT, NB, NV, <u>TG</u> , TJ			
REACT trial			September ivermectin treatment of cattle. goats and sheep in 6 villages of the health district.						
SMC distribution				July-October SP-AQ	July-October SP-AQ	July-October SP-AQ			
ITN distributions	ose that were recruited	July deltamethrin ITN to both RIMDAMAL tria	ls. Underlined clusters ir	n RIMDAMAL II were th	October 29- November 2 α-cypermethin + chlorfenapyr ITN nose randomly selected f	or entomological			

179

Differences in the prevalence of *Plasmodium* species between participants of the RIMDAMAL and RIMDAMAL II trials.

182 The prevalence of blood smear slides from the 2015 RIMDAMAL trial that were positive by

183 microscopy for *Plasmodium* spp. and for different *Plasmodium* species was previously reported,

as was the multiplicity of infection and molecular force of infection in *Pf* positives (58). Here we

report data using molecular analyses on 90 archived blood samples taken from 24 children

aged 0-5 years (split equally from 2 clusters in each arm) who had a fever or history of fever in

187 the prior 24 hours. Of those, 39% (35/90) of tested samples were positive for *Plasmodium*

species and all were *Pf* mono-infections. Overall, 71% (17/24) of these tested children had a

189 molecularly confirmed parasitemia at least once during the trial (Table 2).

190

191 In contrast, in the RIMDAMAL II trial, infections with multiple different *Plasmodium* species were

192 commonly detected in human dried blood spots from 70 randomly chosen RIMDAMAL II

193 participants (split equally from 3 clusters in each arm, and between age grouping and sex) from

our cross-sectional cohort (3 villages per arm) sampled over 2 seasons (2019-2020) (Table 2).

195 Of the 405 samples tested, 56% (225/405) were positive for *Plasmodium* species, and of these

196 72% (161/225) were *Pf* mono-infections and 28% (64/225) were *Pf*-mixed or non-falciparum

197 infections (12% (27/225) *Pf+Pm* co-infections, 5% (12/225) *Pm* mono-infections, 5% (12/225) *Pf*

+ Po co-infections, 2% (4/225) Po mono-infections, 0.4% (1/225) Pf + Pv co-infections, and 3%

199 (7/225) *Pf+Po+Pm* infections). Children 0-5 years old (who took SMC in the trial) more often had

negative blood samples over the trial period relative to participants \geq 6 years old (61% vs. 34%;

201 P < 0.0001) and tended to less often be infected with at least one non-falciparum species over

the trial period relative to participants \geq 6 years old (56% vs. 33%; P = 0.0871). Across all age

203 groups, most non-falciparum infections were detected in one or two cross-sectional blood

samples obtained from individuals throughout the trial period (Figure 2).

205

Table 2. Molecular detection of <i>Plasmodium</i> parasites from participants of the RIMDAMAL trials.																
Trial			Partie	cipants (any le	ongitudinal sa	imple)			Participants' samples							
	ACD cohort (0-5 yrs old)* Participants ≥ 6 yrs old				ACD cohort (0-5 yrs old)*				Participants ≥ 6 yrs old							
	Pf	Pf+nPf	n <i>Pf</i>	neg	Pf	Pf+nPf	n <i>Pf</i>	neg	Pf	Pf+nPf	n <i>Pf</i>	neg	Pf	Pf+nPf	n <i>Pf</i>	neg
RIMDAMAL	71% (17/24)	0% (0/24)	0% (0/24)	29% (7/24)	-	-	-	-	39% (35/90)	0% (0/90)	0% (0/90)	61% (55/90)	-	-	-	-
RIMDAMAL II	59% (16/27)	22% (6/27)	11% (3/27)	7% (2/27)	37% (16/43)	53% (23/43)	2% (1/43)	7% (3/43)	30% (47/156)	5% (8/156)	4% (6/156)	61% (95/156)	46% (114/249)	16% (40/249)	4% (10/249)	34% (85/249)
*ACD: active case detection cohort. In RIMDAMAL, SMC was not yet initiated, but in RIMDAMAL II eligible members of the ACD cohort (those 3-59 month old) were given SMC. Pf. P. falciparum, nPf. P. malariae, P. ovale, P. vivax.																

206

207 Anopheles speciation and blood meal analysis

208 RIMDAMAL entomology data were previously reported (58). Briefly, 2,801 mosquitoes were

209 captured via indoor aspirated of which 99% (2,784/2,801) were morphologically identified as *An*.

210 *gambiae* s.l. These were blood fed mosquitoes that were separated into 1) head+thorax tissue

211 that were previously homogenized and used in sporozoite ELISA assays to detect *Pf*

- 212 circumsporozoite (CSP) protein, and into 2) bloodfed abdomens that were squashed onto filter
- 213 papers cards but then used in other experiments.
- 214

In RIMDAMAL II, a total of 7,942 anopheline mosquitoes were collected (2019, n = 5,827; 2020,

n = 2,115) of which the majority were indoor-captured blood-feds that were held in assays to

217 measure their survival over time. Morphological identification determined the majority to be *An*.

218 *gambiae* sensu lato (s.l.) (85%; 6,745/7,942), with approximately twice the number captured in 219 2019 (n = 4,679) as compared to 2020 (n = 2,066). The remainder were *An. funestus* group

220 mosquitoes (15%; 1,197/7,942) of which 96% (1,148/1,197) came from 2019. A subset of *An*.

- *gambiae* s.l. mosquitoes were further speciated using molecular methods (n= 354). The majority
- were identified as *An. gambiae* (79.4%), followed by *An. coluzzi* (15.5%) and *An. arabiensis*
- 223 (5.1%). Similarly, a subset of *An. funestus* group mosquitoes were further speciated (n = 251)

and the majority were identified as *An. funestus* (96.4%), while a small portion were identified as
 An. rivulorum (3.2%) and *An. leesoni* (0.4%).

226

Blood meal analysis was performed on bloodfed mosquito abdomens from a subset of *An*.

gambiae s.l. and An. funestus complex mosquitoes (n = 171 and 64, respectively). Human

blood meals were detected in most samples from both *An. gambiae* s.l. (81%) and *An. funestus*

230 (68%) (P = 0.0559). Cattle blood meals were the next most abundant but were significantly

231 more prevalent in *An. funestus* (23%; 15/64) than in *An. gambiae* s.l. (6%; 11/171) (P = 0.0006).

Dog, goat, and pig blood meals were detected in both mosquito species, but were uncommon

233 (Figure 3).

234

235 Prevalence of *Plasmodium* parasites species detected in bloodfed and unfed mosquito

236 head-thorax tissues from both trials.

- 237 In RIMDAMAL, the overall sporozoite rate over the intervention period and across arms was
- 4.8% (62/1759; *An. gambiae* s.l. only, head-thoraxes tested by CSP-ELISA) (Table 3).
- 239

Table 3. Sporozoite rates in the RIMDAMAL trials.									
Trial	Mosquito species	Trial arm	Sporozoite rate over trial	P value					
RIMDAMAL	An combioo s l	Control	3.4% (33/961)	-					
	An. yambiae s.i.	Treatment	3.6% (29/798)	0.8207					
RIMDAMAL II	An combine of	Control	5.3% (74/1399)	-					
	An. gambiae S.I.	Treatment	4.3% (48/1129)	0.2626					
	An funestus	Control	20.4% (23/113)	-					
	An. Iunesius	Treatment	11% (15/136)	0.0416					
	An. gambiae s.l. +	Control	6.4% (97/1512)	-					
	An. funestus	Treatment	5% (63/1265)	0.1201					
Sporozoite detection from RIMDAMAL trial was performed using head-thoracies in CSP-ELISA assays using a monoclonal antibody against Pf, while sporozoite detection									

from RIMDAMAL II was performed using head-thoracies in qPCR assays designed to detect *Pf, Po, Pm or Pv* species.

240

From RIMDAMAL II, a total of n = 2,777 mosquito head-thorax samples (n = 2,528 *An. gambiae*

s.I and n = 249 *An. funestus*) were screened for *Plasmodium* sporozoites using species-specific qPCR. The overall sporozoite rate over the intervention period and across arms was 5.8 % (n =

244 160/2,777). In An. gambiae s.l. the overall sporozoite rate across arms was 4.8 % (n =

122/2528) and the most common *Plasmodium* species of sporozoites detected among positives

246 was *Pf* mono infections (65%: 70/122) followed by *Po* mono infections (25%: 31/122) *Pm*

was *Pf* mono-infections (65%; 79/122), followed by *Po* mono-infections (25%; 31/122), *Pm*mono-infections (8%; 10/122), and only two mixed species infections (both *Pf+Po* co-infections;
Figure 4c). In contrast, *An. funestus* had a significantly higher overall sporozoite rate over the

249 intervention period than An. gambiae s.l. (15.3%; 38/249; P < 0.0001). Also, in contrast to An. 250 *gambiae* s.l., the most prevalent sporozoite species detected among positives of An. funestus 251 was Po (63.2%;24/38), followed by Pf and Pm, both at 18.4% (7/38 each) (Figure 4f). Thus, in 252 the RIMDAMAL II trial, the Pf sporozoite rate in An. gambiae s.l. was significantly greater than in 253 An. funestus (P <0.0001), and the Po sporozoite rate in An. funestus was significantly greater 254 than in An. gambiae s.l. (P < 0.0001) from mosquitoes captured in the same villages and houses 255 over the same dates. Furthermore, while the overall sporozoite rates and those from An. 256 gambiae s.l. captured in clusters from treatment or control arms were not significantly different

from one another, sporozoite rates were significantly higher (~2 fold) in the control arm relative to the intervention arm for *An. funestus* (P = 0.0416; Table 3).

259

Prevalence of *Plasmodium* parasites species detected in bloodfed and unfed mosquito abdomens in RIMDAMAL II

262 To better understand the observed differences in sporozoite rates between species and

treatment arms in RIMDAMAL II, we examined a portion of the stored bloodfed and unfed

abdomen samples from each mosquito species and from those that were either sporozoite-

positive or sporozoite-negative. Of the 264 An. gambiae s.l. bloodfed abdomens tested, 75%

- 266 (198/264) were positive for at least one *Plasmodium* species (Figure 4a). Approximately half of
- positives (47%; 93/198) contained parasites of only one species and most often this was *Pf*.
- However, nearly as many (41%; 81/198) contained mixed parasites consisting of *Pf* plus one or
- 269 more non-falciparum species. In contrast, of the An. funestus bloodfed abdomens tested, a

270 significantly lower proportion were *Plasmodium*-positive (52.8%; 47/89; P = 0.0002) (Figure 4d).

271 with the majority (87.2%; 41/47; P < 0.0001) containing parasites of a single species of either

272 Pf, Po or Pm. Overall Plasmodium spp. prevalence in blood fed abdomens was modestly higher

- 273 in sporozoite-positive versus sporozoite-negative mosquitoes, regardless of mosquito species
- 274 (Figure 5). Similarly, mosquitoes captured from treatment arm clusters had a modestly lower
- 275 prevalence of *Plasmodium* spp. than those captured from control arm clusters (Figure 6).
- 276

277 Most unfed abdomens tested negative for parasites (Figure 4b & 4e), in contrast to the blood

278 fed abdomens of the same species (Figure 4a & 4c). Furthermore, *Plasmodium* species

279 prevalence in these unfed abdomens were higher than, but reflective of, the sporozoite-positive

280 head-thoraxes of the different mosquitoes in that only mono-infections were detected. Pf and Po 281 infections were approximately equal among the unfed abdomens of these mosquitoes, but Pm

282 infections of unfed abdomens were only detected in An. funestus (Figure 4b & 4e).

283

Discussion 284

285 The results presented suggest that malaria epidemiology at the study site appears to have

286 changed over a six-year period whereby non-falciparum species have become prevalent, 287 particularly as mixed infections with Pf. The data also suggest that vectors species have

288 differential competence for spreading non-falciparum infections, which may be one novel driver

289 explaining changes in malaria species epidemiology. Unfortunately, standard malaria

290 surveillance performed by the national health authorities, and most other malaria studies in the

291 country over the last decade, have focused on tackling the burden of Pf, and molecular data on

292 the prevalence of non-falciparum species in Burkina Faso is largely lacking. One other

293 published study, however, similarly reported an increase in non-falciparum infections from 2007-294 2010 in central-west Burking Faso in, but entomological indices were not reported (20).

295

296 In addition to entomological factors, anthropogenic factors regarding diagnostics and treatment 297 algorithms have likely driven or influenced the epidemiologic changes observed. Most notably, 298 current POC diagnostics suffer from relatively low sensitivity, requiring peripheral densities of 299 ~100-500 parasites/µL for detection, yet most non-falciparum species tend to maintain lower

300 parasitemias that go undetected (17, 18, 23, 24, 77-79). In addition, while microscopy has the

301 advantage of morphologic-based speciation, this is challenging in practice, particularly in the

302 presence of mixed species infection. With regards to RDTs, nearly 80% of RDTs currently 303 procured in sub-Saharan Africa detect only Pf-specific HRP-2 (80-82). While a second less

304 widely available RDT detects both PfHRP-2 and pan-Plasmodium LDH (83-86), its sensitivity is

305 also low at densities below 1000/µL (25, 87-89). Treatment and prevention guidelines also likely

306 impact species prevalence, as most strategies are explicitly geared towards reducing the Pf

307 burden. In West Africa, the implementation of SMC, including at the site of the RIMDAMAL trials 308 in 2018, has proven to have significant impacts on *Pf* incidence in children, and although it is

309 anticipated that SP-AQ has activity against non-falciparum species, its precise impact on these

310 other species has not been investigated (90-96). Similarly, the impact of ACTs on non-

311 falciparum species is less well studied, and the near-complete lack of usage of 8-

312 aminoquinolines directed at the dormant liver stages of Po and Pv in Africa results in a

313 persisting reservoir of infection even if blood-stage therapy is initiated. In a 2-year study of

314 malaria prevalence in Niger during and after SMC distributions, cross sectional microscopy 315 surveys detected Pf alone in the high and low seasons of year 1, but subsequently detected 316 mixed- and mono-infections with Po and Pm in year 2 (97). In our RIMDAMAL trials, incidence 317 in 0 to 5 year olds dropped approximately 80% between 2015 and 2019 (58) (ClinicalTrials.gov: 318 NCT03967054), presumably due to SMC commencing in 2018, but parasite prevalence 319 remained exceedingly high in both trials suggesting a limited ability of SMC to affect parasite 320 prevalence in this high transmission setting. Malaria incidence among the child cohort in 321 RIMDAMAL II dropped further in 2020 across both arms, which is likely connected to the activity 322 of dual chemistry nets distributed in both trial arms. It is also possibly that an increase in non-323 falciparum parasite species at the field site may have contributed to the overall reduction in 324 malaria incidence via our active case detection procedures between the two RIMDAMAL trials 325 given that the pyrogenic thresholds of non-falciparum species are likely to be lower than Pf (98) 326 from considerably lower parasitemias and shorter durations of patent infections (23, 24, 99, 327 100).

328

329 The abundance of An. funestus in RIMDAMAL II during the 2019 rainy season was unexpected 330 considering our data from previous seasons (39, 41, 58). Typically, this vector increases at the 331 very end of the rainy season and persists through the early, 'cold' dry season (late October -332 February), a time when An. gambiae s.l. populations fall dramatically. Its presence is connected 333 to more permanent water sources with emergent vegetation (42, 101) that remain following the 334 cessation of the seasonal rains. An. funestus was highly prevalent at the study site in human landing catches performed during dry season sampling between 2017-8 during the REACT trial 335 336 (75). Its abnormally high density so early in the year in 2019 may be related to the wetter-than-337 average rainy season (Figure 1) where it could take advantage of the more abundant, possibly 338 deeper water breeding sites across the landscape due to the excess water. Regardless, the 339 opportunity to catch both An. gambiae s.l. and An. funestus, especially the blood feds, in the 340 same households over the same timeframes allowed for novel insights into potential differential 341 vector competence between An. gambiae and An. funestus in our area.

342

343 The tested blood fed abdomens of both mosquito species would be expected to contain a mix of 344 newly ingested parasites (both asexual forms and gametocytes) from mostly human blood 345 meals that were taken the night prior to capture, as well a smaller proportion of developing early 346 sporogonic stages in and on the midgut tissues of mosquitoes that were infected from an earlier 347 blood meal. The unfed abdomens, being from host-seeking mosquitoes captured in the same 348 households as the blood feds, provided a measure of the proportion of mosquitoes already 349 containing those developing sporogonic stages, which was 21.6% for An. gambiae s.l. and 350 38.2% for An. funestus. Considering the proportions of negative abdominal tissues between 351 blood feds and unfeds, the data suggest An. gambiae s.l. are exposed to parasites upon blood 352 feeding nearly twice as often as An. funestus, likely from higher human biting rates that we 353 observed from this mosquito, and potentially also from a higher propensity to blood feed on 354 multiple people over a single night (102). The data also show that mixed-parasite species blood 355 meals, which we surprisingly observed often in the human samples too, were present nearly five 356 times as often among An. gambiae s.l. than An. funestus, but mixed infections were not 357 detected in unfed abdomens of either mosquito species, and only detected twice in thoraxes as

358 sporozoites. Dividing the unfed abdomen infection rates by the blood fed abdomen parasite rate 359 can provide a rough approximation of successful midgut infection in the wild for both mosquito 360 species, which was only 29% of the time for An. gambiae s.l. but approximately 72% of the time 361 for An, funestus. Examination of infected unfed abdomens compared to sporozoite infections in 362 the positive head+thorax tissues suggests that successful parasite development from early to 363 late sporogonic forms may be similarly more restrictive in An. gambiae s.l. (22%) than in An. 364 funestus (40%). Lastly, the differences observed in the prevalence of different Plasmodium 365 species across the tissues of the two mosquitoes is notable. These data suggest that while An. 366 *funestus* was less often exposed to parasites during blood feeding, the exposure was more 367 often as mono-infections and parasite infection was more often successful. Furthermore, An. 368 funestus was preferentially infected with Pm or Po, but complete sporogonic development to 369 sporozoites more often favored Po. In contrast, An. gambiae s.l. captured at the same 370 timepoints and from the same households was more often exposed to parasites during blood 371 feeding and up to 40% may have been mixed-infection exposures, but parasite infections were 372 less successful. Furthermore, midgut infections in An. gambiae s.l. (unfed abdomens) were 373 nearly always of a single parasite species which was typically *Pf* and *Po*, but *Pf* more often 374 successfully developed into sporozoites.

375

376 Given these are observational entomological and human data, there are several non-mutually 377 exclusive hypotheses that could explain the findings. Most obviously, data may reflect true 378 vector competence differences of mosquito species for different parasite species, such as 379 parasite exflagellation, fertilization or sporogonic development being enhanced for Po in An. 380 funestus, or the inverse whereby these are inhibited for Pm and Po in An. gambiae, perhaps via 381 innate immune targeting mechanisms (103). This may be an observation of emergent co-382 speciation between vector and parasite species. Parasite species sporogony competition, either 383 directly or for resources in the mosquito, may also contributing to preferential vector 384 competence outcomes in one mosquito species over the other (104-108). Lastly, factors 385 influencing vectorial capacity may also help explain some of these observations. The An. 386 funestus we captured blood fed more often on cattle, which may explain some of the parasite 387 prevalence data in blood fed abdomens, but another possibility is that An. funestus preferentially 388 blood fed on human hosts with different parasite species relative to An. gambiae, possibly due 389 to a preference for certain attractive odors given off by the infected host dependent on the 390 parasite species they were infected with (109). Some of the results may also be explained by 391 differences in vector blood meal sizes or vector lifespans, such as if most of the An. funestus 392 mosquitoes are longer-lived and therefore more likely to have non-falciparum sporozoites which 393 develop less rapidly than Pf, or mortality in the field due to certain combinations of parasite and 394 vector, for example if Pm sporogonic development increases An. gambiae s.l. mortality. We are 395 not aware of previous field reports on co-speciation or preferential sporogonic development of certain Plasmodium species over others in different species of vector anophelines. Molecular 396 397 detection of *Plasmodium* in mosquitoes captured from the field in African settings remains 398 relatively rare due to the costs of performing qPCR on numerous individual mosquito samples 399 with different molecular probes. More often ELISA assays are used to save costs, but these are 400 often only used with antibodies to Pf or Pv alone (110) and are relatively insensitive and prone 401 to false positives when compared to molecular analyses (111-113). Also, for molecular analyses

- 402 of mosquitoes, the most efficient molecular targets are also still being compared (114, 115), as
- 403 are the dissection methods to ensure the fewest false positives (116). We chose to dissect at
- 404 the junction of the midgut and abdomen, however, the large differences in parasite prevalence
- 405 between blood fed abdomens compared to unfed abdomens and head+thoracies suggests our
- 406 analyses was not overly biased from parasite contamination across mosquito tissues.
- 407 Regardless, this was a comparative analysis between mosquito species.
- 408

409 Importantly, this study has several limitations. Foremost, these longitudinal data are confined to

- 410 a single field site and must be tested to determine their generalizability. It is possible that the
- results are partially related to the ivermectin or other intervention activities occurring at the site.
 Regarding the human data, we had limitations from our more limited testing of archived samples
- 413 from the RIMDAMAL trial, including that the blood samples tested were only from symptomatic
- 414 children. Retrospective molecular analysis of mosquito tissues from the RIMDAMAL trial were
- 415 also not possible due to the samples having been used in prior assays. Follow-up blood
- sampling and testing should be performed at the site to determine if the change in prevalence
- from *Pf* to more non-*falciparum* species persists or increases over time, and if non-*falciparum*
- 418 infections are correlated with presence of *An. funestus* or increased rainfall during the wet
- 419 season in other areas. While the entomological data are a measure of natural infection
- 420 outcomes, the analyses are associative being based on observational data alone and so they
- should be validated using mosquito feeding assays with the blood from infectious participants.
- 422

423 Conclusion

- The data presented here show that malaria parasite species prevalence in humans changed
- 425 dramatically in the Diebougou health district in southwest Burkina Faso over the period
- 426 bracketing the two RIMDAMAL trials occurring five years apart, and when SMC was initiated at
- 427 the site in between the two trials. The parasite species changed from almost exclusively being
- 428 *Pf* to a high prevalence of non-falciparum species mixed with *Pf* or occurring alone.
- 429 Furthermore, evidence suggests that non-falciparum species were preferentially transmitted by
- 430 An. funestus while Pf was preferentially transmitted by An. gambiae s.l. These formative studies
- 431 should be followed up with more rigorous testing of the hypotheses regarding vector
- 432 competence or vectorial capacity differences for *Plasmodium* parasites between the different
- 433 mosquito species and may explain the changing malaria epidemiology in areas of sub-Saharan
- 434 Africa where a diversity of anopheles vectors exist or are in flux.
- 435

436 Methods

- 437 Study area, experimental design, and adult mosquito collection
- 438 The Diebougou health district in southwestern Burkina Faso experiences a single long rainy
- 439 season from approximately June-November (39). The RIMDAMAL trial spanned one rainy
- 440 season (July-November) in 2015, and RIMDAMAL II spanned rainy seasons (July-November) in
- two consecutive years, 2019 and 2020 and both were conducted in this health district. Detailed
- information about both trials is available elsewhere (58, 59). Briefly, in RIMDAMAL, 8 village
- 443 clusters were studied and 4 were randomized to the intervention arm consisting of 6 ivermectin
- 444 MDAs (single dose of 150 μ g/kg) for eligible participants every 3 weeks over one season, while
- the other 4 were randomized to the control arm consisting of a single ivermectin MDA (single

446 dose of 150 µg/kg) for eligible participants at the beginning of the season. In RIMDAMAL II, 14 447 village clusters were studied and 7 were randomized to the intervention arm consisting of 4 448 ivermectin MDA (3 consecutive daily doses of 300 µg/kg) for eligible participants once per 449 month over 4 months of the season, while the other 7 were randomized to the control arm 450 consisting of placebo administered in the same manner. To estimate spatiotemporal variations 451 in land surface wetness in the study area, Normalized Difference Moisture Index (NDMI), a 452 measure of vegetation moisture content, was assessed from 2015-2020. NDMI was measured 453 from Landsat 8 Level 2, Collection 2, Tier 1 satellite images at 30-m resolution. Satellite images 454 were obtained from the rainy seasons (May to October) and median NDMI calculated for each 455 year from near infrared and short-wave infrared bands after cloud masking in Google Earth 456 Engine.

457

Anopheline mosquito sampling in both trials was performed similarly, in 8 households from each
 village in RIMDAMAL and from 8 households in each of 3 villages per arm in RIMDAMAL II,

- 460 whereby most mosquitoes captured were resting indoor blood feds and aspirated from walls and
- 461 ceilings in the mornings, and additional capture of host-seeking mosquitoes was performed
- using light traps located a single centrally located house per village placed indoors next to a
- 463 person sleeping under a bed net and outdoors next to a person sleeping in a tent. In
- 464 RIMDAMAL, mosquito collections occurred on the 2nd week follow each MDA, and in
- RIMDAMAL II on the 1st and 3rd weeks following each MDA. Participants' blood from these same
- households was also serially sampled across the intervention periods to allow linking of
 parasitology and entomology outcomes. After collection, mosquitoes were morphologically
- 468 identified in the field station as either *An. gambiae* s.l., *An. funestus* complex, or other species,
- 469 and molecular analyses were performed subsequently in laboratories.
- 470

471 **DNA extraction from dried human blood spots**

472 Dried blood spots (DBS) on filter paper cards were made in RIMDAMAL from active case 473 detection (ACD) cohort children whose blood was sampled during febrile episodes occurring 474 during the trial. DBS from 24 of these randomly chosen participants who were living in the 4 475 villages that were also enrolled in RIMDAMAL II (Table 1; KP, TJ, DK, TG) and which were also 476 sampled for mosquitoes were tested for *Plasmodium* species. In RIMDAMAL II, serially 477 collected DBS were collected from participants of all ages from households that were also 478 sampled for mosquitoes, and DBS from 100 of these randomly chosen participants were tested 479 for *Plasmodium* species. DNA was extracted from 3mm hole punches of each DBS by 480 incubating them overnight in a 60°C shaking incubator with PBS and proteinase K and the 481 supernatant process with a Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek) using the 482 KingFisher Flex Magnetic Particle Processor (Thermo Fisher Scientific). DNA was eluted in 30

- 483 μ L of nuclease-free water and stored at -80° C prior to testing.
- 484

485 **DNA extraction from RIMDAMAL II mosquito tissues**

486 Female Anopheline head+thoraces stored in RNALater® (Thermo Fisher Scientific) were

- 487 removed from tubes and blotted on absorbent paper to remove excess liquid. Samples were
- 488 then individually placed in new tubes with 300 μL mosquito diluent containing 20% of FBS, 100
- 489 μ g/mL of streptomycin, 100 units/mL of penicillin, 50 μ g/mL gentamicin, and 2.5 μ g/mL

490 fungizone in PBS. Samples were homogenized by a single zinc-plated, steel 4.5 mm bead for 491 1.5 minutes at 24 Hz before being centrifuged for 5 minutes at 14,000 x g at 4°C. DNA was 492 extracted from all samples using the Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek) using 493 the KingFisher Flex Magnetic Particle Processor (Thermo Fisher Scientific). DNA was eluted in 494 30 µL of nuclease-free water and stored at -80°C. Abdomen samples were placed in 2.0 mL 495 tubes with one 4-5 mm steel bead, TL buffer, and proteinase K solution provided by the Mag 496 Bind Blood and Tissue Kit HDQ 96 kit (Omega Bio-Tek). Each sample was homogenized (50 497 oscillation for 5 minutes), centrifuged (8,000 rpm for 30 seconds), and incubated in a 56°C dry 498 bath overnight. The next day, homogenates were extracted using a KingFisher™ Flex 499 Purification System (Thermo Fisher Scientific). DNA was eluted in 100 uL of nuclease-free 500 water and yields were quantified using a Nanodrop device (ThermoFisher Scientific) to 501 determine the success of extraction. Once quantified, samples were stored at -80°C until further 502 analysis.

503

504 Anopheles speciation

505 Morphological identification of wild-caught An. funestus and An. gambiae s.l. mosquitoes was 506 done using standard taxonomic key in the field (117, 118). In a MiniAmp PlusThermocycler, An. 507 gambiae s.l. were further speciated following PCR assay which amplified a region of the 508 intergenic spacer 2 (119) to identify An. gambiae, An. coluzzii and An. arabiensis. To further 509 speciate mosquitoes belonging to the An. funestus complex, a portion of the ITS2 gene was 510 amplified following the method of Koekemoer et al. (120), and subsequently sequenced. The 511 DNA sequences were aligned in Mesquite (121), and the Anopheles species was determined by 512 comparing the sequences with those found in the GeneBank nucleotide database.

513

514 *Plasmodium* detection in both human and mosquito samples

515 To detect the presence of Pf, Po, Pm and Pv in the head+thorax and/or abdomen tissues, two 516 real-time PCRs were done. Pf DNA was detected using the assay described by Hoffman et al. 517 (122), which detects *P. falciparum* DNA in mosquito tissues by amplifying the var gene acidic 518 terminal sequence (varATS). Po, Pm and Pv were detected following the protocol described by 519 Phuong et al. (123), which targets the 18S rRNA gene. Pf samples that amplified at or before 36 520 cycles and showed a logarithmic amplification curve were interpreted as positive. The positive 521 controls for Pf were DNA from Plasmodium-infected DBS generated from in vitro culture at 522 various ranges of parasitemia placed on filter paper, from which 3 mm punches were placed in 523 PCR tubes with 70 µL Rapid Extraction Solution (Thermo Fisher Scientific) and rocked overnight 524 at 4°C and the DNA was purified using the same procedure as described for head+thorax. 525 Negative controls were DNA extracts from malaria-negative DBS. Po, Pm and Pv were detected 526 following the protocol described by Phuong et al. (123), which involved using species-specific 527 forward primers and probes targeting the 18S rRNA gene. Po was identified using a probe 528 labeled with VIC at the 5' end and a minor groove binding quencher at the 3' end. Pv was 529 detected using a probe labeled with TAMRA at the 5' end and a BHQ-2 guencher at the 3' end. 530 Pm was identified using a probe labeled with FAM at the 5' end and a minor groove binding 531 quencher at the 3' end. The same reverse primer was used for all species identification. 532 Nuclease-free water served as the negative control, while linearized, clean DNA from the 533 plasmid clones (MRA numbers 177–180; BEI Resources, NIH, NIAID) acted as both positive

controls. All head+thorax samples that showed logarithmic amplification at or before 36 cycles
were interpreted as positive. All PCR reactions were performed in a QuantStudio 3 real-time
PCR instrument (Thermo Fisher Scientific).

537

538 Blood meal analysis

539 A conventional PCR followed by a 1.5% electrophoresis gel was done to analyze the host blood 540 meal of mosquito abdomen samples, following the methods described by Kent et al. (124),

- 541 which amplifies a region of the cytochrome b mitochondrial gene and includes primers to identify
- 542 blood meals from dog, human, cow, pig, and goat host species. The electrophoresis gel ran at
- 543 90 volts for 45 minutes and was imaged on a BIO-RAD ChemiDoc MP Imaging System for 544 analysis.
- 545

546 Statistical analysis

547 Data was analyzed on GraphPad Prism or R (R-project.org). Chi-square tests and Fisher's

- 548 exact test were performed, depending on the number of variables. Chi-square test for trend
- 549 tests for linear trends between variables, while the Fisher's exact test tests for association
- between variables, and both assess the chances of observing the trend/association in random
- sampling (GraphPad Prism Version 9.3.1). A P value less than 0.05 was interpreted as
- 552 statistically significant.
- 553

554 Data Availability

555 All RIMDAMAL II data will be deposited in ClinEpiDB.org and be available for analysis and 556 download under the terms of set by the website.

- 557
- 558

559 Figures

560

- 561
- 562



NDMI calculated for each year. **A)** Map of relative wetness at the study site and clusters (outlined in black) **B)** Temporal variation in mean study site NDMI. Dashed line indicates overall median value. **C)** Spatial variation in NDMI at each cluster (all years).

563

598 599







637

749 **References**

750 1. World Health Programme. World Malaria Report 2023. Geneva: 2023.

751 2. Institut National de la Statistique et de la Démographie (INSD) PdAaD, Sanitaire (PADS)
752 PNdLclPPel. Enquête sur les indicateurs du paludisme au Burkina Faso. Rockville, Maryland,
753 USA: 2018.

754 3. Yaro JB, Tiono AB, Ouedraogo A, Lambert B, Ouedraogo ZA, Diarra A, Traore A,

Lankouande M, Soulama I, Sanou A, Worrall E, Agboraw E, Sagnon N, Ranson H, Churcher

TS, Lindsay SW, Wilson AL. Risk of Plasmodium falciparum infection in south-west Burkina

Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention. Sci Rep.
2022;12(1):1402. doi: 10.1038/s41598-022-05056-7. PubMed PMID: 35082312; PMCID:

- 759 PMC8791962.
- Sangare I, Ouattara CA, Soma DD, Soma D, Assogba BS, Namountougou M, Tougri G,
 Savadogo LB. Spatial-temporal pattern of malaria in Burkina Faso from 2013 to 2020. Parasite
 Epidemiol Control. 2022;18:e00261. doi: 10.1016/j.parepi.2022.e00261. PubMed PMID:
 35859938; PMCID: PMC9289732.
- 5. Bationo C, Cissoko M, Katile A, Sylla B, Ouedraogo A, Ouedraogo JB, Tougri G,
 Kompaore SCB, Moiroux N, Gaudart J. Malaria in Burkina Faso: A comprehensive analysis of
 spatiotemporal distribution of incidence and environmental drivers, and implications for control
 strategies. PLoS One. 2023;18(9):e0290233. doi: 10.1371/journal.pone.0290233. PubMed
 PMID: 37703223; PMCID: PMC10499254.
- 6. US Presidents Malaria Initiative. U.S. President's Malaria Initiative Burkina Faso Malaria
 Operational Plan FY 2024. U.S. President's Malaria Initiative 2023.
- 771 7. United Nations Development Programme. Human Development Report 2021-22:
 772 Uncertain Times, Unsettled Lives: Shaping our Future in a Transforming World. New York:
 773 2022.
- Rouamba T, Nakanabo-Diallo S, Derra K, Rouamba E, Kazienga A, Inoue Y, Ouedraogo
 EK, Waongo M, Dieng S, Guindo A, Ouedraogo B, Sallah KL, Barro S, Yaka P, Kirakoya Samadoulougou F, Tinto H, Gaudart J. Socioeconomic and environmental factors associated
 with malaria hotspots in the Nanoro demographic surveillance area, Burkina Faso. BMC Public
 Health. 2019;19(1):249. doi: 10.1186/s12889-019-6565-z. PubMed PMID: 30819132; PMCID:
 PMC6396465.
- 9. Guglielmo F, Ranson H, Sagnon N, Jones C. The issue is not 'compliance': exploring
 exposure to malaria vector bites through social dynamics in Burkina Faso. Anthropol Med.
 2021;28(4):508-25. doi: 10.1080/13648470.2021.1884185. PubMed PMID: 33970705; PMCID:
 PMC7613283.
- Allan-Blitz LT, Goldfine C, Erickson TB. Environmental and health risks posed to children
 by artisanal gold mining: A systematic review. SAGE Open Med. 2022;10:20503121221076934.
 doi: 10.1177/20503121221076934. PubMed PMID: 35173966; PMCID: PMC8841918.
- Boukaré B. The development impact of "gold rushes" in Mali and Burkina Faso: the
 multifaceted effects of migration on artisanal gold mining sites. In: Fargues F, M. Rango, E.
 Börgnas and I. Schöfberger, editor. Migration in West and North Africa and across the
 Mediterranean. Geneva2020.
- Mediterranean. Geneva2020.
 Mueller I, Schoepflin S, Smith TA, Benton KL, Bretscher MT, Lin E, Kiniboro B,
 Zimmerman PA, Speed TP, Siba P, Felger I. Force of infection is key to understanding the
 epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl
 Acad Sci U S A. 2012;109(25):10030-5. Epub 2012/06/06. doi: 10.1073/pnas.1200841109.
 PubMed PMID: 22665809; PMCID: 3382533.
- 798 Felger I, Farnert A. Multiplicity of Asymptomatic Plasmodium falciparum Infections and Risk of

799 Clinical Malaria: A Systematic Review and Pooled Analysis of Individual Participant Data, J 800 Infect Dis. 2020;221(5):775-85. doi: 10.1093/infdis/jiz510. PubMed PMID: 31585009; PMCID: 801 PMC7026891. 802 14. Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka 803 FT, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite 804 extended artemether-lumefantrine treatment in children. Nat Commun. 2024;15(1):3817. doi: 805 10.1038/s41467-024-48210-7. PubMed PMID: 38714692; PMCID: PMC11076639. 806 Sondo P, Derra K, Rouamba T, Nakanabo Diallo S, Taconet P, Kazienga A, Ilboudo H, 15. 807 Tahita MC, Valea I, Sorgho H, Lefevre T, Tinto H. Determinants of Plasmodium falciparum 808 multiplicity of infection and genetic diversity in Burkina Faso. Parasit Vectors. 2020;13(1):427. 809 doi: 10.1186/s13071-020-04302-z. PubMed PMID: 32819420; PMCID: PMC7441709. 810 Ehrlich HY, Some AF, Bazie T, Ebou CN, Dembele EL, Balma R, Goodwin J, Wade M, 16. 811 Bei AK, Ouedraogo JB, Foy BD, Dabire RK, Parikh S. Tracking antimalarial drug resistance 812 using mosquito blood meals: a cross-sectional study. Lancet Microbe. 2023. doi: 813 10.1016/S2666-5247(23)00063-0. PubMed PMID: 37086737. 814 Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale--17. 815 the "bashful" malaria parasites. Trends Parasitol. 2007;23(6):278-83. doi: 816 10.1016/j.pt.2007.04.009. PubMed PMID: 17459775; PMCID: PMC3728836. 817 Roh ME, Oyet C, Orikiriza P, Wade M, Kiwanuka GN, Mwanga-Amumpaire J, Parikh S, 18. 818 Boum Y, 2nd. Asymptomatic Plasmodium Infections in Children in Low Malaria Transmission 819 Setting, Southwestern Uganda(1). Emerg Infect Dis. 2016;22(8):1494-8. doi: 820 10.3201/eid2208.160619. PubMed PMID: 27434741; PMCID: PMC4982177. 821 Sendor R, Banek K, Kashamuka MM, Mvuama N, Bala JA, Nkalani M, Kihuma G, Atibu 19. 822 J, Thwai KL, Svec WM, Goel V, Nseka T, Lin JT, Bailey JA, Emch M, Carrel M, Juliano JJ, 823 Tshefu A, Parr JB. Epidemiology of Plasmodium malariae and Plasmodium ovale spp. in 824 Kinshasa Province, Democratic Republic of Congo. Nat Commun. 2023;14(1):6618. doi: 825 10.1038/s41467-023-42190-w. PubMed PMID: 37857597; PMCID: PMC10587068 Abbott 826 Laboratories, and consulting for Zymeron Corporation, all outside the scope of this study. The 827 remaining authors declare no competing interests. 828 Gneme A, Guelbeogo WM, Riehle MM, Tiono AB, Diarra A, Kabre GB, Sagnon N, 20. 829 Vernick KD. Plasmodium species occurrence, temporal distribution and interaction in a child-830 aged population in rural Burkina Faso. Malar J. 2013;12:67. Epub 2013/02/21. doi: 831 10.1186/1475-2875-12-67. PubMed PMID: 23421809; PMCID: 3583752. 832 Heinemann M, Phillips RO, Vinnemeier CD, Rolling CC, Tannich E, Rolling T. High 21. 833 prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018. Malar J. 834 2020;19(1):366. doi: 10.1186/s12936-020-03441-z. PubMed PMID: 33046056; PMCID: 835 PMC7552528. 836 22. Agonhossou R, Akoton R, Lagnika H, Djihinto OY, Sovegnon PM, Saizonou HD, Ntoumi 837 F, Wondji CS, Borrmann S, Adegnika AA, Djogbenou LS. P. falciparum msp1 and msp2 genetic 838 diversity in P. falciparum single and mixed infection with P. malariae among the asymptomatic 839 population in Southern Benin. Parasitol Int. 2022;89:102590. doi: 10.1016/j.parint.2022.102590. 840 PubMed PMID: 35472441. 841 Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, Canque B, Legros F, Badji A, 23. 842 Ndiaye G, Ndiaye P, et al. The Dielmo project: a longitudinal study of natural malaria infection 843 and the mechanisms of protective immunity in a community living in a holoendemic area of 844 Senegal. Am J Trop Med Hyg. 1994;51(2):123-37. doi: 10.4269/ajtmh.1994.51.123. PubMed 845 PMID: 8074247. 846 Faye FB, Konate L, Rogier C, Trape JF. Plasmodium ovale in a highly malaria endemic 24. 847 area of Senegal. Trans R Soc Trop Med Hyg. 1998;92(5):522-5. doi: 10.1016/s0035-848 9203(98)90900-2. PubMed PMID: 9861368.

Yerlikaya S, Campillo A, Gonzalez IJ. A Systematic Review: Performance of Rapid
Diagnostic Tests for the Detection of Plasmodium knowlesi, Plasmodium malariae, and
Plasmodium ovale Monoinfections in Human Blood. J Infect Dis. 2018;218(2):265-76. doi:
10.1093/infdis/iiy150. PubMed PMID: 29554284; PMCID: PMC6009649.

853 26. World Health Organization. Testing for G6PD deficiency for safe use of primaquine in 854 radical cure of P. vivax and P. ovale malaria 2016.

Diabate A, Dabire RK, Kengne P, Brengues C, Baldet T, Ouari A, Simard F, Lehmann T.
Mixed swarms of the molecular M and S forms of Anopheles gambiae (Diptera: Culicidae) in
sympatric area from Burkina Faso. J Med Entomol. 2006;43(3):480-3. doi: 10.1603/00222585(2006)43[480:msotmm]2.0.co;2. PubMed PMID: 16739404.

- 859 28. Fournet F, Cussac M, Ouari A, Meyer PE, Toe HK, Gouagna LC, Dabire RK. Diversity in
 860 anopheline larval habitats and adult composition during the dry and wet seasons in
 861 Ouagadougou (Burkina Faso). Malar J. 2010;9:78. doi: 10.1186/1475-2875-9-78. PubMed
 862 PMID: 20298619; PMCID: PMC2907872.
- Wondji CS, Dabire RK, Tukur Z, Irving H, Djouaka R, Morgan JC. Identification and
 distribution of a GABA receptor mutation conferring dieldrin resistance in the malaria vector
 Anopheles funestus in Africa. Insect Biochem Mol Biol. 2011;41(7):484-91. doi:
- 866 10.1016/j.ibmb.2011.03.012. PubMed PMID: 21501685; PMCID: PMC3579012.
- 30. Gimonneau G, Pombi M, Choisy M, Morand S, Dabire RK, Simard F. Larval habitat
 segregation between the molecular forms of the mosquito Anopheles gambiae in a rice field
 area of Burkina Faso, West Africa. Med Vet Entomol. 2012;26(1):9-17. doi: 10.1111/j.13652915.2011.00957.x. PubMed PMID: 21501199; PMCID: PMC3140611.
- 31. Namountougou M, Simard F, Baldet T, Diabate A, Ouedraogo JB, Martin T, Dabire RK.
 Multiple insecticide resistance in Anopheles gambiae s.l. populations from Burkina Faso, West
 Africa. PLoS One. 2012;7(11):e48412. Epub 2012/11/29. doi: 10.1371/journal.pone.0048412.
 PubMed PMID: 23189131; PMCID: 3506617.
- 32. Dabire RK, Namountougou M, Sawadogo SP, Yaro LB, Toe HK, Ouari A, Gouagna LC,
 Simard F, Chandre F, Baldet T, Bass C, Diabate A. Population dynamics of Anopheles gambiae
 s.l. in Bobo-Dioulasso city: bionomics, infection rate and susceptibility to insecticides. Parasit
 Vectors. 2012;5:127. Epub 2012/06/23. doi: 10.1186/1756-3305-5-127. PubMed PMID:
 22721002; PMCID: 3424103.
- Namountougou M, Diabate A, Etang J, Bass C, Sawadogo SP, Gnankinie O, Baldet T,
 Martin T, Chandre F, Simard F, Dabire RK. First report of the L1014S kdr mutation in wild
 populations of Anopheles gambiae M and S molecular forms in Burkina Faso (West Africa).
- Acta Trop. 2013;125(2):123-7. Epub 2012/11/07. doi: 10.1016/j.actatropica.2012.10.012.
- 884 PubMed PMID: 23128044.
- 885 34. Niang A, Epopa PS, Sawadogo SP, Maiga H, Konate L, Faye O, Dabire RK, Tripet F,
 886 Diabate A. Does extreme asymmetric dominance promote hybridization between Anopheles
 887 coluzzii and Anopheles gambiae s.s. in seasonal malaria mosquito communities of West Africa?
- Parasit Vectors. 2015;8:586. doi: 10.1186/s13071-015-1190-x. PubMed PMID: 26559354;
 PMCID: PMC4642620.
- Biggin St. Hidalgo K, Montazeau C, Siaussat D, Braman V, Trabalon M, Simard F, Renault D,
 Dabire RK, Mouline K. Distinct physiological, biochemical and morphometric adjustments in the
 malaria vectors Anopheles gambiae and A. coluzzii as means to survive dry season conditions
 in Burkina Faso. The Journal of experimental biology. 2018;221(Pt 6). doi: 10.1242/jeb.174433.
 PubMed PMID: 29378815.
- 895 36. Gildenhard M, Rono EK, Diarra A, Boissiere A, Bascunan P, Carrillo-Bustamante P,
- Camara D, Kruger H, Mariko M, Mariko R, Mireji P, Nsango SE, Pompon J, Reis Y, Rono MK,
- 897 Seda PB, Thailavil J, Traore A, Yapto CV, Awono-Ambene P, Dabire RK, Diabate A, Masiga D,
- 898 Catteruccia F, Morlais I, Diallo M, Sangare D, Levashina EA. Mosquito microevolution drives

Plasmodium falciparum dynamics. Nat Microbiol. 2019;4(6):941-7. doi: 10.1038/s41564-0190414-9. PubMed PMID: 30911126; PMCID: PMC7613322.

901 37. Namountougou M, Soma DD, Kientega M, Balbone M, Kabore DPA, Drabo SF, 902 Coulibaly AY, Fournet F, Baldet T, Diabate A, Dabire RK, Gnankine O. Insecticide resistance 903 mechanisms in Anopheles gambiae complex populations from Burkina Faso, West Africa. Acta 904 Trop. 2019;197:105054. doi: 10.1016/j.actatropica.2019.105054. PubMed PMID: 31175862. 905 38. Epopa PS, Collins CM, North A, Millogo AA, Benedict MQ, Tripet F, Diabate A. Seasonal 906 malaria vector and transmission dynamics in western Burkina Faso. Malar J. 2019;18(1):113. 907 doi: 10.1186/s12936-019-2747-5. PubMed PMID: 30940141; PMCID: PMC6444393. 908 Soma DD, Zogo BM, Some A, Tchiekoi BN, Hien DFS, Pooda HS, Coulibaly S, 39. 909 Gnambani JE, Ouari A, Mouline K, Dahounto A, Ouedraogo GA, Fournet F, Koffi AA, Pennetier 910 C, Moiroux N, Dabire RK. Anopheles bionomics, insecticide resistance and malaria transmission 911 in southwest Burkina Faso: A pre-intervention study. PLoS One. 2020;15(8):e0236920. doi: 912 10.1371/journal.pone.0236920. PubMed PMID: 32745085; PMCID: PMC7398507. 913 Dabire KR. Baldet T. Diabate A. Dia I. Costantini C. Cohuet A. Guiguemde TR. 40. 914 Fontenille D. Anopheles funestus (Diptera: Culicidae) in a humid savannah area of western 915 Burkina Faso: bionomics, insecticide resistance status, and role in malaria transmission. J Med 916 Entomol. 2007;44(6):990-7. doi: 10.1603/0022-2585(2007)44[990:afdcia]2.0.co;2. PubMed 917 PMID: 18047197. 918 41. Soma DD, Poda SB, Hien AS, Namountougou M, Sangare I, Sawadogo JME, Fournet F, 919 Ouedraogo GA, Diabate A, Moiroux N, Dabire RK, Malaria vectors diversity, insecticide 920 resistance and transmission during the rainy season in peri-urban villages of south-western 921 Burkina Faso. Malar J. 2021;20(1):63. doi: 10.1186/s12936-020-03554-5. PubMed PMID: 922 33494779; PMCID: PMC7831184. 923 42. Taconet P, Porciani A, Soma DD, Mouline K, Simard F, Koffi AA, Pennetier C, Dabire 924 RK, Mangeas M, Moiroux N. Data-driven and interpretable machine-learning modeling to 925 explore the fine-scale environmental determinants of malaria vectors biting rates in rural Burkina 926 Faso. Parasit Vectors. 2021;14(1):345. doi: 10.1186/s13071-021-04851-x. PubMed PMID: 927 34187546: PMCID: PMC8243492. 928 Epopa PS, Millogo AA, Collins CM, North AR, Benedict MQ, Tripet F, O'Loughlin S, 43. 929 Dabire RK, Ouedraogo GA, Diabate A. Anopheles gambiae (s.l.) is found where few are looking: 930 assessing mosquito diversity and density outside inhabited areas using diverse sampling 931 methods. Parasit Vectors. 2020;13(1):516. doi: 10.1186/s13071-020-04403-9. PubMed PMID: 932 33059722; PMCID: PMC7558606. 933 Mawejje HD, Kilama M, Kigozi SP, Musiime AK, Kamya M, Lines J, Lindsey SW, Smith 44. 934 D, Dorsey G, Donnelly MJ, Staedke SG. Impact of seasonality and malaria control interventions 935 on Anopheles density and species composition from three areas of Uganda with differing 936 malaria endemicity. Malaria J. 2021:20(1). doi: doi: 10.1186/s12936-021-03675-5. 937 O'Meara WP, Simmons R, Bullins P, Freedman B, Abel L, Mangeni J, Taylor SM, Obala 45. 938 AA. Mosquito Exposure and Malaria Morbidity: A Microlevel Analysis of Household Mosquito 939 Populations and Malaria in a Population-Based Longitudinal Cohort in Western Kenya. J Infect 940 Dis. 2020;221(7):1176-84. doi: 10.1093/infdis/jiz561. PubMed PMID: 31665350; PMCID: 941 PMC7325711. 942 46. Morlais I, Nsango SE, Toussile W, Abate L, Annan Z, Tchioffo MT, Cohuet A, Awono-943 Ambene PH, Fontenille D, Rousset F, Berry A. Plasmodium falciparum mating patterns and 944 mosquito infectivity of natural isolates of gametocytes. PLoS One. 2015;10(4):e0123777. doi: 945 10.1371/journal.pone.0123777. PubMed PMID: 25875840; PMCID: PMC4397039. 946 Das S, Muleba M, Stevenson JC, Pringle JC, Norris DE. Beyond the entomological 47. 947 inoculation rate: characterizing multiple blood feeding behavior and Plasmodium falciparum

948 multiplicity of infection in Anopheles mosquitoes in northern Zambia. Parasit Vectors.

949 2017:10(1):45. doi: 10.1186/s13071-017-1993-z. PubMed PMID: 28122597: PMCID: 950 PMC5267472. 951 48. Kanatani S, Stiffler D, Bousema T, Yenokyan G, Sinnis P. Revisiting the Plasmodium 952 sporozoite inoculum and elucidating the efficiency with which malaria parasites progress 953 through the mosquito. Nat Commun. 2024;15(1):748. doi: 10.1038/s41467-024-44962-4. 954 PubMed PMID: 38272943; PMCID: PMC10811227. 955 Andolina C, Graumans W, Guelbeogo M, van Gemert GJ, Ramijth J, Harouna S, 49. 956 Soumanaba Z, Stoter R, Vegte-Bolmer M, Pangos M, Sinnis P, Collins K, Staedke SG, Tiono 957 AB, Drakeley C, Lanke K, Bousema T. Quantification of sporozoite expelling by Anopheles 958 mosquitoes infected with laboratory and naturally circulating P. falciparum gametocytes. Elife. 959 2024;12. doi: 10.7554/eLife.90989. PubMed PMID: 38517746; PMCID: PMC10959522. 960 Pampiglioni S, Majori G, Petrangeli G, Romi R. Avermectins, MK-933 and MK-936, for 50. 961 mosquito control. Trans R Soc Trop Med Hyg. 1985;79:797-9. 962 Crump A, Omura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. 51. 963 Proceedings of the Japan Academy Series B. Physical and biological sciences. 2011;87(2):13-964 28. Epub 2011/02/16. PubMed PMID: 21321478; PMCID: 3043740. 965 52. Bockarie MJ, Hii JL, Alexander ND, Bockarie F, Dagoro H, Kazura JW, Alpers MP. Mass 966 treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito 967 survival. Med Vet Entomol. 1999;13(2):120-3. PubMed PMID: 10484157. 968 53. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes 969 fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 970 2010;202(1):113-6. PubMed PMID: 20482251. 971 Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug 54. 972 administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J 973 Trop Med Hyg. 2011:85(1):3-5. Epub 2011/07/08. doi: 10.4269/aitmh.2011.11-0160. PubMed 974 PMID: 21734116; PMCID: 3122335. 975 Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, Gimnig J, 55. 976 Samuels A, Desai M, Phillips-Howard PA, Kariuki S, Wang D, Ward S, Ter Kuile FO. Efficacy 977 and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for 978 a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR 979 Res Protoc. 2016;5(4):e213. doi: 10.2196/resprot.6617. PubMed PMID: 27856406; PMCID: 980 PMC5133431. 981 56. The Ivermectin Roadmappers, Billingsley P, Binka F, Chaccour C, Foy B, Gold S, 982 Gonzalez-Silva M, Jacobson J, Jagoe G, Jones C, Kachur P, Kobylinski K, Last A, Lavery JV, Mabey D, Mboera D, Mbogo C, Mendez-Lopez A, Rabinovich NR, Rees S, Richards F, Rist C, 983 984 Rockwood J, Ruiz-Castillo P, Sattabongkot J, Saute F, Slater H, Steer A, Xia K, Zullinger R. A 985 Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool. 986 Am J Trop Med Hyg. 2020;102(2s):3-24. doi: 10.4269/ajtmh.19-0620. PubMed PMID: 987 31971144; PMCID: PMC7008306. 988 Kositz C, Bradley J, Hutchins H, Last A, D'Alessandro U, Marks M. Broadening the 57. 989 range of use cases for ivermectin - a review of the evidence. Trans R Soc Trop Med Hyg. 990 2022;116(3):201-12. doi: 10.1093/trstmh/trab114. PubMed PMID: 34323283; PMCID: 991 PMC8890779. 992 Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, 58. 993 Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabate A, Coulidiaty AGV, Rouamba N, 994 Dabire RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control 995 of malaria (RIMDAMAL): a cluster-randomised trial. Lancet. 2019. doi: 10.1016/S0140-996 6736(18)32321-3. PubMed PMID: 30878222. 997 Foy BD, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson CL, Kittelson J, 59. 998 Slater HC, Bousema T, Da O, Coulidiaty AGV, Colt M, Wade M, Richards K, Some AF, Dabire 999 RK, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a

Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of
Malaria. JMIR Res Protoc. 2023;12:e41197. doi: 10.2196/41197. PubMed PMID: 36939832;
PMCID: PMC10132043.

1003 60. Dabira ED, Soumare HM, Lindsay SW, Conteh B, Ceesay F, Bradley J, Kositz C,
1004 Broekhuizen H, Kandeh B, Fehr AE, Nieto-Sanchez C, Ribera JM, Peeters Grietens K, Smit
1005 MR, Drakeley C, Bousema T, Achan J, D'Alessandro U. Mass Drug Administration With High1006 Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low
1007 Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV
1008 Cluster Randomized Clinical Trial. JMIR Res Protoc. 2020;9(11):e20904. doi: 10.2196/20904.
1009 PubMed PMID: 33211022; PMCID: PMC7714640.

- Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H, Jones RT, Ndiath
 MO, Dit Massire Soumare H, Mabey D, Nante EJ, Martins C, Logan JG, Slater H, Drakeley C,
 D'Alessandro U, Rodrigues A, Last AR. Protocol for a cluster randomised placebo-controlled
 trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagos
- Archipelago of Guinea-Bissau: the MATAMAL trial. BMJ Open. 2023;13(7):e072347. doi: 10.1126/bmienen.2023.072347. DubMod DMID: 27410628; DMCID: DMC10325573
- 1015 10.1136/bmjopen-2023-072347. PubMed PMID: 37419638; PMCID: PMC10335573.
 1016 62. Chaccour C, Casellas A, Hammann F, Ruiz-Castillo P, Nicolas P, Montana J, Mael M,
- 1017 Selvaraj P, Duthaler U, Mrema S, Kakolwa M, Lyimo I, Okumu F, Marathe A, Schurch R,
- 1018 Elobolobo E, Sacoor C, Saute F, Xia K, Jones C, Rist C, Maia M, Rabinovich NR. BOHEMIA:
- 1019 Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-
- 1020 randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug
- administration to reduce malaria transmission in two African settings. Trials. 2023;24(1):128.
 doi: 10.1186/s13063-023-07098-2. PubMed PMID: 36810194; PMCID: PMC9942013.
- 1022 doi: 10.1186/s13063-023-07098-2. PubMed PMID: 36810194; PMCID: PMC994201
- 1023 63. World Health Organization. World Malaria Report 2023.
- 1024 64. Taylor SM, Messina JP, Hand CC, Juliano JJ, Muwonga J, Tshefu AK, Atua B, Emch M,
 1025 Meshnick SR. Molecular malaria epidemiology: mapping and burden estimates for the
 1026 Democratic Republic of the Congo, 2007. PLoS One. 2011;6(1):e16420. doi:
- 1027 10.1371/journal.pone.0016420. PubMed PMID: 21305011; PMCID: PMC3031549.
- 1028 65. Woldearegai TG, Lalremruata A, Nguyen TT, Gmeiner M, Veletzky L, Tazemda-Kuitsouc
 1029 GB, Matsiegui PB, Mordmuller B, Held J. Characterization of Plasmodium infections among
 1030 inhabitants of rural areas in Gabon. Sci Rep. 2019;9(1):9784. doi: 10.1038/s41598-019-461941031 9. PubMed PMID: 31278305; PMCID: PMC6611864.
- 66. Abdulraheem MA, Ernest M, Ugwuanyi I, Abkallo HM, Nishikawa S, Adeleke M,
 Orimadegun AE, Culleton R. High prevalence of Plasmodium malariae and Plasmodium ovale
 in co-infections with Plasmodium falciparum in asymptomatic malaria parasite carriers in
 southwestern Nigeria. Int J Parasitol. 2022;52(1):23-33. doi: 10.1016/j.ijpara.2021.06.003.
 PubMed PMID: 34390743.
- 1037 67. Amoah LE, Asare KK, Dickson D, Anang SF, Busayo A, Bredu D, Asumah G, Peprah N,
 1038 Asamoah A, Abuaku B, Malm KL. Nationwide molecular surveillance of three Plasmodium
 1039 species harboured by symptomatic malaria patients living in Ghana. Parasit Vectors.
- 1040 2022;15(1):40. doi: 10.1186/s13071-022-05153-6. PubMed PMID: 35090545; PMCID:
- 1041 PMC8796507.
- 1042 68. Amoah LE, Donu D, Abuaku B, Ahorlu C, Arhinful D, Afari E, Malm K, Koram KA.
 1043 Probing the composition of Plasmodium species contained in malaria infections in the Eastern
 1044 region of Ghana. BMC Public Health. 2019;19(1):1617. doi: 10.1186/s12889-019-7989-1.
 1045 PubMed PMID: 31791319; PMCID: PMC6889690.
- 1046 69. Nguiffo-Nguete D, Nongley Nkemngo F, Ndo C, Agbor JP, Boussougou-Sambe ST,
 1047 Salako Djogbenou L, Ntoumi F, Adegnika AA, Borrmann S, Wondji CS. Plasmodium malariae
- 1048 contributes to high levels of malaria transmission in a forest-savannah transition area in
- 1049 Cameroon. Parasit Vectors. 2023;16(1):31. doi: 10.1186/s13071-022-05635-7. PubMed PMID:
- 1050 36698132; PMCID: PMC9875470.

1051 70. Oriero EC, Olukosi AY, Oduwole OA, Djimde A, D'Alessandro U, Meremikwu MM,
1052 Amambua-Ngwa A. Seroprevalence and Parasite Rates of Plasmodium malariae in a High
1053 Malaria Transmission Setting of Southern Nigeria. Am J Trop Med Hyg. 2020;103(6):2208-16.
1054 doi: 10.4269/ajtmh.20-0593. PubMed PMID: 33124531; PMCID: PMC7695047.

1055 71. Quaye IK, Aleksenko L, Oeuvray C, Yewhalaw D, Duah N, Gyan B, Haiyambo DH,
1056 Dongho GBD, Torgby RA, Amoah L, Hamid MA, Worku S, Bahiti AA, Pasquale HA, Bitshi M,
1057 Troare I, Diarra A, Njunju E, Cisse M, Soulama I, Savadogo RJ, Issifou S, Niangaly A, Dembele
1058 L, Greco B. The Pan African Vivax and Ovale Network (PAVON): Refocusing on Plasmodium
1059 vivax, ovale and asymptomatic malaria in sub-Saharan Africa. Parasitol Int. 2021;84:102415.
1060 doi: 10.1016/j.parint.2021.102415. PubMed PMID: 34216801.

- 1061 72. Sendor R, Mitchell CL, Chacky F, Mohamed A, Mhamilawa LE, Molteni F, Nyinondi S,
 1062 Kabula B, Mkali H, Reaves EJ, Serbantez N, Kitojo C, Makene T, Kyaw T, Muller M, Mwanza A,
 1063 Eckert EL, Parr JB, Lin JT, Juliano JJ, Ngasala B. Similar Prevalence of Plasmodium falciparum
 1064 and Non-P. falciparum Malaria Infections among Schoolchildren, Tanzania(1). Emerg Infect Dis.
 1065 2023;29(6):1143-53. doi: 10.3201/eid2906.221016. PubMed PMID: 37209670; PMCID:
 1066 PMC10202886.
- 1067 73. Hawadak J, Dongang Nana RR, Singh V. Global trend of Plasmodium malariae and
 1068 Plasmodium ovale spp. malaria infections in the last two decades (2000-2020): a systematic
 1069 review and meta-analysis. Parasit Vectors. 2021;14(1):297. doi: 10.1186/s13071-021-04797-0.
 1070 PubMed PMID: 34082791; PMCID: PMC8173816.
- 1071 74. Sagna AB, Zela L, Ouedraogo COW, Pooda SH, Porciani A, Furnival-Adams J, Lado P,
 1072 Some AF, Pennetier C, Chaccour CJ, Dabire RK, Mouline K. Ivermectin as a novel malaria
 1073 control tool: Getting ahead of the resistance curse. Acta Trop. 2023;245:106973. doi:
 1074 1016/i actatropica 2023 106073. DubMed DMID: 27252009
- 1074 10.1016/j.actatropica.2023.106973. PubMed PMID: 37352998.
- 1075 75. Taconet P, Zogo B, Soma DD, Ahoua Alou LP, Mouline K, Dabire RK, Amanan Koffi A,
 1076 Pennetier C, Moiroux N. Anopheles sampling collections in the health districts of Korhogo (Cote
 1077 d'Ivoire) and Diebougou (Burkina Faso) between 2016 and 2018. GigaByte.
- 1078 2023;2023:gigabyte83. doi: 10.46471/gigabyte.83. PubMed PMID: 37408730; PMCID: 1079 PMC10318348.
- 1080 76. McMahon A, Franca CMB, Wimberly MC. Comparing Satellite and Ground-Based
- 1081 Measurements of Environmental Suitability for Vector Mosquitoes in an Urban Landscape. J
- Med Entomol. 2022;59(6):1936-46. doi: 10.1093/jme/tjac145. PubMed PMID: 36189969;
 PMCID: PMC9667728.
- 1084 77. Snounou G, Pinheiro L, Goncalves A, Fonseca L, Dias F, Brown KN, do Rosario VE.
- 1085 The importance of sensitive detection of malaria parasites in the human and insect hosts in
- epidemiological studies, as shown by the analysis of field samples from Guinea Bissau. Trans R
 Soc Trop Med Hyg. 1993;87(6):649-53. doi: 10.1016/0035-9203(93)90274-t. PubMed PMID:
- 1088 8296364.
- 1089 78. Nsobya SL, Parikh S, Kironde F, Lubega G, Kamya MR, Rosenthal PJ, Dorsey G.
 1090 Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children. J
 1001 Infect Dia 2004;180(12):2220 6. doi: 10.1086/421281. BubMod BMID: 15181560.
- 1091 Infect Dis. 2004;189(12):2220-6. doi: 10.1086/421281. PubMed PMID: 15181569.
- 1092 79. Murphy SC, Shott JP, Parikh S, Etter P, Prescott WR, Stewart VA. Malaria diagnostics in
 1093 clinical trials. Am J Trop Med Hyg. 2013;89(5):824-39. doi: 10.4269/ajtmh.12-0675. PubMed
 1094 PMID: 24062484; PMCID: PMC3820323.
- 1095 80. Beadle C, Long GW, Weiss WR, McElroy PD, Maret SM, Oloo AJ, Hoffman SL.
- 1096 Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick 1097 antigen-capture assay. Lancet. 1994;343(8897):564-8. doi: 10.1016/s0140-6736(94)91520-2. 1098 PubMed PMID: 7906328.
- 1099 81. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria
- 1100 Diagnosis, but with Caveats. Trends Parasitol. 2020;36(2):112-26. doi:
- 1101 10.1016/j.pt.2019.12.004. PubMed PMID: 31848119.

1102 82. WHO. World Malaria Report 2023. Geneva: World Health Organization. 2023. 1103 83. Singh B. Molecular methods for diagnosis and epidemiological studies of parasitic infections. Int J Parasitol. 1997;27(10):1135-45. doi: 10.1016/s0020-7519(97)00111-2. PubMed 1104 1105 PMID: 9394184. Abba K. Deeks JJ. Olliaro P. Naing CM. Jackson SM. Takwoingi Y. Donegan S. Garner 1106 84. 1107 P. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic 1108 countries. The Cochrane database of systematic reviews. 2011;2011(7):CD008122. doi: 1109 10.1002/14651858.CD008122.pub2. PubMed PMID: 21735422; PMCID: PMC6532563. 1110 85. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin 1111 Microbiol Infect. 2013;19(5):399-407. doi: 10.1111/1469-0691.12151. PubMed PMID: 1112 23438048. 1113 Jimenez A, Rees-Channer RR, Perera R, Gamboa D, Chiodini PL, Gonzalez IJ, Mayor 86. 1114 A, Ding XC. Analytical sensitivity of current best-in-class malaria rapid diagnostic tests. Malar J. 2017;16(1):128. doi: 10.1186/s12936-017-1780-5. PubMed PMID: 28340585; PMCID: 1115 1116 PMC5366122. 1117 Farcas GA, Zhong KJ, Lovegrove FE, Graham CM, Kain KC. Evaluation of the Binax 87. 1118 NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in 1119 returned travelers. Am J Trop Med Hyg. 2003;69(6):589-92. PubMed PMID: 14740873. 1120 Ratsimbasoa A, Randriamanantena A, Raherinjafy R, Rasoarilalao N, Menard D. Which 88. 1121 malaria rapid test for Madagascar? Field and laboratory evaluation of three tests and expert 1122 microscopy of samples from suspected malaria patients in Madagascar. Am J Trop Med Hyg. 1123 2007;76(3):481-5. PubMed PMID: 17360871. 1124 Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR. Multiplex real-time quantitative PCR, 89. 1125 microscopy and rapid diagnostic immuno-chromatographic tests for the detection of 1126 Plasmodium spp: performance, limit of detection analysis and quality assurance. Malar J. 1127 2009;8:284. doi: 10.1186/1475-2875-8-284. PubMed PMID: 20003199; PMCID: PMC2796674. 1128 Sokhna C, Cisse B, Ba el H, Milligan P, Hallett R, Sutherland C, Gaye O, Boulanger D, 90. 1129 Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF. A trial of the efficacy, 1130 safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive 1131 treatment for malaria in Senegalese children. PLoS One. 2008;3(1):e1471. doi: 1132 10.1371/journal.pone.0001471. PubMed PMID: 18213379; PMCID: PMC2198946. 1133 91. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Diawara H, Conare 1134 T, Djimde A, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B. 1135 Intermittent preventive treatment of malaria provides substantial protection against malaria in 1136 children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, 1137 placebo-controlled trial. PLoS Med. 2011;8(2):e1000407. doi: 10.1371/journal.pmed.1000407. 1138 PubMed PMID: 21304923; PMCID: PMC3032550. 1139 Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M. 92. 1140 Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, 1141 Ghana: an individually randomised clinical trial. Trop Med Int Health. 2016;21(2):224-35. doi: 1142 10.1111/tmi.12642. PubMed PMID: 26578353; PMCID: PMC4982104. Cisse B, Ba EH, Sokhna C, JL ND, Gomis JF, Dial Y, Pitt C, M ND, Cairns M, Faye E, M 1143 93. 1144 ND, Lo A, Tine R, Faye S, Faye B, Sy O, Konate L, Kouevijdin E, Flach C, Faye O, Trape JF, 1145 Sutherland C, Fall FB, Thior PM, Faye OK, Greenwood B, Gaye O, Milligan P. Effectiveness of 1146 Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-1147 Wedge Cluster-Randomised Trial. PLoS Med. 2016;13(11):e1002175. doi: 1148 10.1371/journal.pmed.1002175. PubMed PMID: 27875528; PMCID: PMC5119693. 1149 Diawara SI, Konate D, Kaventao K, Mihigo J, Shaffer JG, Sangare M, Ndabamenye P, 94. 1150 Swedberg E, Garg LW, Gamache N, Keita B, Kamate B, Ndaruhutse P, Kone D, Sanogo V, 1151 Tounkara M, Diakite M, Doumbia S, Eckert E. Effect of seasonal malaria chemoprevention in 1152 children between 5 and 9 years old in Kita and Bafoulabe districts, Mali. Parasite Epidemiol

1153 Control. 2022;18:e00258. doi: 10.1016/j.parepi.2022.e00258. PubMed PMID: 35789762; 1154 PMCID: PMC9249800. 1155 95. Ansah PO, Ansah NA, Malm K, Awuni D, Peprah N, Dassah S, Yarig S, Manful C, 1156 Agbenyeri J, Awoonor-Williams J, Ofosu W, Oduro AR. Evaluation of pilot implementation of 1157 seasonal malaria chemoprevention on morbidity in young children in Northern Sahelian Ghana. 1158 Malar J. 2021;20(1):440. doi: 10.1186/s12936-021-03974-x. PubMed PMID: 34794431; PMCID: 1159 PMC8600740. 1160 Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, Nikiema F, 96. 1161 Tapily A, Sompougdou F, Issiaka D, Zoungrana C, Sanogo K, Haro A, Kaya M, Sienou AA, Traore S, Mahamar A, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, 1162 1163 Ofori-Anvinam O, Tinto H, Djimde A, Ouedraogo JB, Dicko A, Greenwood B. Seasonal Malaria 1164 Vaccination with or without Seasonal Malaria Chemoprevention. N Engl J Med. 1165 2021;385(11):1005-17. doi: 10.1056/NEJMoa2026330. PubMed PMID: 34432975. 1166 Coldiron ME, Assao B, Guindo O, Sayinzoga-Makombe N, Koscalova A, Sterk E, Quere 97. 1167 M. Ciglenecki I. Mumina A. Atti S. Langendorf C. Grais RF. Prevalence of malaria in an area 1168 receiving seasonal malaria chemoprevention in Niger. Malar J. 2021;20(1):419. doi: 1169 10.1186/s12936-021-03953-2. PubMed PMID: 34689782; PMCID: PMC8543849. 1170 Faye FB, Spiegel A, Tall A, Sokhna C, Fontenille D, Rogier C, Trape JF. Diagnostic 98. 1171 criteria and risk factors for Plasmodium ovale malaria. J Infect Dis. 2002;186(5):690-5. doi: 1172 10.1086/342395. PubMed PMID: 12195357. 1173 Collins WE, Jeffery GM, Plasmodium malariae: parasite and disease. Clin Microbiol Rev. 99. 1174 2007;20(4):579-92. doi: 10.1128/CMR.00027-07. PubMed PMID: 17934075; PMCID: 1175 PMC2176047. 1176 Collins WE, Jeffery GM. Plasmodium ovale: parasite and disease. Clin Microbiol Rev. 100. 1177 2005;18(3):570-81. doi: 10.1128/CMR.18.3.570-581.2005. PubMed PMID: 16020691; PMCID: 1178 PMC1195966. 1179 101. Nambunga IH, Ngowo HS, Mapua SA, Hape EE, Msugupakulya BJ, Msaky DS, 1180 Mhumbira NT, McHwembo KR, Tamayamali GZ, Mlembe SV, Njalambaha RM, Lwetoijera DW, 1181 Finda MF, Govella NJ, Matoke-Muhia D, Kaindoa EW, Okumu FO. Aquatic habitats of the 1182 malaria vector Anopheles funestus in rural south-eastern Tanzania. Malar J. 2020;19(1):219. 1183 doi: 10.1186/s12936-020-03295-5. PubMed PMID: 32576200; PMCID: PMC7310514. 1184 Scott TW, Takken W. Feeding strategies of anthropophilic mosquitoes result in 102. 1185 increased risk of pathogen transmission. Trends Parasitol. 2012;28(3):114-21. doi: 1186 10.1016/j.pt.2012.01.001. PubMed PMID: 22300806. 1187 Bartholomay LC, Michel K. Mosquito Immunobiology: The Intersection of Vector Health 103. 1188 and Vector Competence. Annu Rev Entomol. 2018;63:145-67. doi: 10.1146/annurev-ento-1189 010715-023530. PubMed PMID: 29324042. 1190 104. McKenzie FE. Bossert WH. Mixed-species Plasmodium infections of Anopheles 1191 (Diptera:Culicidae). J Med Entomol. 1997;34(4):417-25. doi: 10.1093/jmedent/34.4.417. 1192 PubMed PMID: 9220675; PMCID: PMC2500223. 1193 Shaw WR, Marcenac P, Catteruccia F. Plasmodium development in Anopheles: a tale of 105. 1194 shared resources. Trends Parasitol. 2022;38(2):124-35. doi: 10.1016/j.pt.2021.08.009. PubMed 1195 PMID: 34548252; PMCID: PMC8758519. 1196 106. Arez AP, Pinto J, Palsson K, Snounou G, Jaenson TG, do Rosario VE. Transmission of 1197 mixed Plasmodium species and Plasmodium falciparum genotypes. Am J Trop Med Hyg. 1198 2003;68(2):161-8. PubMed PMID: 12641406. 1199 107. Imwong M, Nakeesathit S, Day NP, White NJ. A review of mixed malaria species 1200 infections in anopheline mosquitoes. Malar J. 2011;10:253. doi: 10.1186/1475-2875-10-253. 1201 PubMed PMID: 21880138; PMCID: PMC3201030. 1202 Balasubramanian S, Rahman RS, Lon C, Parobek C, Ubalee R, Hathaway N, 108. 1203 Kuntawunginn W, My M, Vy D, Saxe J, Lanteri C, Lin FC, Spring M, Meshnick SR, Juliano JJ,

- 1204 Saunders DL, Lin JT. Efficient Transmission of Mixed Plasmodium falciparum/vivax Infections
- 1205 From Humans to Mosquitoes. J Infect Dis. 2020;221(3):428-37. doi: 10.1093/infdis/jiz388.
- 1206 PubMed PMID: 31549156; PMCID: PMC7184918.
- 1207 109. Robinson A, Busula AO, Voets MA, Beshir KB, Caulfield JC, Powers SJ, Verhulst NO,
- 1208 Winskill P, Muwanguzi J, Birkett MA, Smallegange RC, Masiga DK, Mukabana WR, Sauerwein
- 1209 RW, Sutherland CJ, Bousema T, Pickett JA, Takken W, Logan JG, de Boer JG. Plasmodium-
- 1210 associated changes in human odor attract mosquitoes. Proc Natl Acad Sci U S A.
- 2018;115(18):E4209-E18. doi: 10.1073/pnas.1721610115. PubMed PMID: 29666273; PMCID:
 PMC5939094.
- 1213 110. MR4. Methods in Anopheles Research 2014. Available from:
- 1214 <u>https://www.beiresources.org/portals/2/MR4/MR4_Publications/Methods%20in%20Anopheles%</u>
 1215 <u>20Research%202014/2014MethodsinAnophelesResearchManualFullVersionv2tso.pdf</u>
- 1216 111. Burkot TR, Zavala F, Gwadz RW, Collins FH, Nussenzweig RS, Roberts DR.
- 1217 Identification of malaria-infected mosquitoes by a two-site enzyme-linked immunosorbent assay.
 1218 Am J Trop Med Hyg. 1984;33(2):227-31. doi: 10.4269/ajtmh.1984.33.227. PubMed PMID:
- 1219 6370003.
- 1220 112. Beier JC, Perkins PV, Koros JK, Onyango FK, Gargan TP, Wirtz RA, Koech DK, Roberts
- 1221 CR. Malaria sporozoite detection by dissection and ELISA to assess infectivity of afrotropical
- 1222 Anopheles (Diptera: Culicidae). J Med Entomol. 1990;27(3):377-84. doi:
- 1223 10.1093/jmedent/27.3.377. PubMed PMID: 2185363.
- 1224 113. Durnez L, Van Bortel W, Denis L, Roelants P, Veracx A, Trung HD, Sochantha T,
- 1225 Coosemans M. False positive circumsporozoite protein ELISA: a challenge for the estimation of 1226 the entomological inoculation rate of malaria and for vector incrimination. Malar J. 2011;10:195.
- 1227 doi: 10.1186/1475-2875-10-195. PubMed PMID: 21767376; PMCID: PMC3160429.
- 1228 114. Echeverry DF, Deason NA, Makuru V, Davidson J, Xiao H, Niedbalski J, Yu X,
- 1229 Stevenson JC, Bugoro H, Aparaimo A, Reuben H, Cooper R, Burkot TR, Russell TL, Collins FH,
- Lobo NF. Fast and robust single PCR for Plasmodium sporozoite detection in mosquitoes using the cytochrome oxidase I gene. Malar J. 2017;16(1):230. doi: 10.1186/s12936-017-1881-1.
- the cytochrome oxidase I gene. Malar J. 2017;16(1):230. doi: 10.1186/s12936-017-1881-1.
 PubMed PMID: 28569159; PMCID: PMC5452387.
- 1233 115. Ogola EO, Fillinger U, Ondiba IM, Villinger J, Masiga DK, Torto B, Tchouassi DP.
- Insights into malaria transmission among Anopheles funestus mosquitoes, Kenya. Parasit
 Vectors. 2018;11(1):577. doi: 10.1186/s13071-018-3171-3. PubMed PMID: 30400976; PMCID:
- 1236 PMC6219006.
- 1237 116. Foley DH, Harrison G, Murphy JR, Dowler M, Rueda LM, Wilkerson RC. Mosquito
- 1238 bisection as a variable in estimates of PCR-derived malaria sporozoite rates. Malar J.
- 1239 2012;11:145. doi: 10.1186/1475-2875-11-145. PubMed PMID: 22551078; PMCID:
- 1240 PMC3411414.
- 1241 117. Diagne N, Fontenille D, Konate L, Faye O, Lamizana MT, Legros F, Molez JF, Trape JF.
 1242 [Anopheles of Senegal. An annotated and illustrated list]. Bull Soc Pathol Exot. 1994;87(4):2671243 77. PubMed PMID: 7866049.
- 1244 118. Gillies MT, Coetzee M. A supplement to the Anophelinae of Africa South of the Sahara 1245 (Afrotropical Region). S Afr Inst Med Res. 1987:143.
- 1246 119. Wilkins EE, Howell PI, Benedict MQ. IMP PCR primers detect single nucleotide
- 1247 polymorphisms for Anopheles gambiae species identification, Mopti and Savanna rDNA types,
- and resistance to dieldrin in Anopheles arabiensis. Malar J. 2006;5:125. doi: 10.1186/1475 2875-5-125. PubMed PMID: 17177993; PMCID: PMC1769388.
- 1250 120. Koekemoer LL, Kamau L, Hunt RH, Coetzee M. A cocktail polymerase chain reaction 1251 assay to identify members of the Anopheles funestus (Diptera: Culicidae) group. Am J Trop Med 1252 Hyg. 2002;66(6):804-11. doi: 10.4269/ajtmh.2002.66.804. PubMed PMID: 12224596.
- 1253 121. Maddison WP, Maddison DR. Mesquite: a modular system for evolutionary analysis.1254 2021.

- 1255 122. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
 1256 detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS
 1257 Med. 2015;12(3):e1001788. doi: 10.1371/journal.pmed.1001788. PubMed PMID: 25734259;
 1257 DM240404000
- 1258 PMCID: PMC4348198.
- 1259 123. Phuong M, Lau R, Ralevski F, Boggild AK. Sequence-based optimization of a
- 1260 quantitative real-time PCR assay for detection of Plasmodium ovale and Plasmodium malariae.
- 1261 J Clin Microbiol. 2014;52(4):1068-73. doi: 10.1128/JCM.03477-13. PubMed PMID: 24430459;
- 1262 PMCID: PMC3993485.
- 1263 124. Kent RJ, Norris DE. Identification of mammalian blood meals in mosquitoes by a
- 1264 multiplexed polymerase chain reaction targeting cytochrome B. Am J Trop Med Hyg.
- 1265 2005;73(2):336-42. PubMed PMID: 16103600; PMCID: PMC4147110.
- 1266